lovastatin trial summary

Cardiovascular prevention

All chronical situations: 10 trials - CCAIT - MARS - AFCAPS/TexCAPS - Excel - Weintraub - CRISP 20mg - ACAPS - Sahni - CLAPT - CRISP 40mg

lovastatin vs placebo

Coronary event by 24% (fully demonstrated)

suggested Coronary death and non fatal MI by 24% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	0.62 [0.34 1.13]	p=1.00	0	7524	2	AFCAPS/TexCAPS,ACAPS,
stroke (fatal and non fatal)	0.73 [0.36 1.45]	p=1.00	0	7524	2	AFCAPS/TexCAPS,ACAPS,
Coronary event	0.76 [0.61 0.93]	p=0.04	0	6605	1	AFCAPS/TexCAPS,
Coronary death and non fatal MI	0.76 [0.61 0.93]	p=0.04	0	6605	1	AFCAPS/TexCAPS,
Coronary death	1.02 [0.57 1.83]	p=1.00	0	16754	6	CCAIT,MARS,AFCAPS/TexCAPS,Excel,Weintraub,ACAPS,
cardiac death	0.11 [0.01 2.07]	p=1.00	0	919	1	ACAPS,
MACE	no data
Non fatal MI	0.91 [0.38 2.17]	p=1.00	0	1250	2	CCAIT,ACAPS,
All cause death	1.09 [0.81 1.46]	p=1.00	0	16751	6	CCAIT,MARS,AFCAPS/TexCAPS,Excel,Weintraub,ACAPS,
non cardiovascular death	1.19 [0.84 1.71]	p=1.00	0	16754	6	CCAIT,MARS,AFCAPS/TexCAPS,Excel,Weintraub,ACAPS,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	0.98 [0.70 1.38]	p=1.00	0	6211	1	AFCAPS/TexCAPS,
Death from cancer	no data
Rhabdomyolysis	0.50 [0.08 3.07]	p=1.00	0	15769	3	AFCAPS/TexCAPS,Excel,ACAPS,
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

lovastatin vs usual care

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	no data
Coronary death and non fatal MI	no data
Coronary death	0.49 [0.09 2.78]	p=1.00	0	157	1	Sahni,
cardiac death	0.20 [0.01 4.29]	p=1.00	0	226	1	CLAPT,
MACE	no data
Non fatal MI	0.20 [0.01 4.29]	p=1.00	0	226	1	CLAPT,
All cause death	0.63 [0.18 2.18]	p=1.00	0	383	2	Sahni,CLAPT,
non cardiovascular death	1.65 [0.21 12.93]	p=1.00	0	383	2	Sahni,CLAPT,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	no data
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

See more clinical conditions

Diabetic patients: 2 trials - CRISP 20mg - CRISP 40mg

lovastatin vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	no data
Coronary death and non fatal MI	no data
Coronary death	no data
cardiac death	no data
MACE	no data
Non fatal MI	no data
All cause death	no data
non cardiovascular death	no data
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	no data
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Elderly: 1 trials - CRISP 20mg

lovastatin vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	no data
Coronary death and non fatal MI	no data
Coronary death	no data
cardiac death	no data
MACE	no data
Non fatal MI	no data
All cause death	no data
non cardiovascular death	no data
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	no data
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Patients with LDL elevation and without CHD: 1 trials - AFCAPS/TexCAPS

lovastatin vs placebo

Coronary event by 24% (fully demonstrated)

suggested Coronary death and non fatal MI by 24% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	0.68 [0.37 1.26]	p=1.00	0	6605	1	AFCAPS/TexCAPS,
stroke (fatal and non fatal)	0.82 [0.40 1.67]	p=1.00	0	6605	1	AFCAPS/TexCAPS,
Coronary event	0.76 [0.61 0.93]	p=0.04	0	6605	1	AFCAPS/TexCAPS,
Coronary death and non fatal MI	0.76 [0.61 0.93]	p=0.04	0	6605	1	AFCAPS/TexCAPS,
Coronary death	0.73 [0.34 1.60]	p=1.00	0	6605	1	AFCAPS/TexCAPS,
cardiac death	no data
MACE	no data
Non fatal MI	no data
All cause death	1.04 [0.76 1.42]	p=1.00	0	6605	1	AFCAPS/TexCAPS,
non cardiovascular death	1.21 [0.84 1.75]	p=1.00	0	6605	1	AFCAPS/TexCAPS,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	0.98 [0.70 1.38]	p=1.00	0	6211	1	AFCAPS/TexCAPS,
Death from cancer	no data
Rhabdomyolysis	0.50 [0.05 5.51]	p=1.00	0	6605	1	AFCAPS/TexCAPS,
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Patients with other atherosclerotic localisation: 1 trials - ACAPS

lovastatin vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	0.08 [0.00 1.37]	p=1.00	0	919	1	ACAPS,
stroke (fatal and non fatal)	0.09 [0.01 1.65]	p=1.00	0	919	1	ACAPS,
Coronary event	no data
Coronary death and non fatal MI	no data
Coronary death	0.11 [0.01 2.07]	p=1.00	0	919	1	ACAPS,
cardiac death	0.11 [0.01 2.07]	p=1.00	0	919	1	ACAPS,
MACE	no data
Non fatal MI	1.00 [0.29 3.47]	p=1.00	0	919	1	ACAPS,
All cause death	0.12 [0.02 1.00]	p=1.00	0	919	1	ACAPS,
non cardiovascular death	0.50 [0.05 5.52]	p=1.00	0	919	1	ACAPS,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	no data
Rhabdomyolysis	1.00 [0.02 50.40]	p=1.00	0	919	1	ACAPS,
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Patients with prior MI or with CHD: 2 trials - Sahni - CLAPT

lovastatin vs usual care

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	no data
Coronary death and non fatal MI	no data
Coronary death	0.49 [0.09 2.78]	p=1.00	0	157	1	Sahni,
cardiac death	0.20 [0.01 4.29]	p=1.00	0	226	1	CLAPT,
MACE	no data
Non fatal MI	0.20 [0.01 4.29]	p=1.00	0	226	1	CLAPT,
All cause death	0.63 [0.18 2.18]	p=1.00	0	383	2	Sahni,CLAPT,
non cardiovascular death	1.65 [0.21 12.93]	p=1.00	0	383	2	Sahni,CLAPT,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	no data
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Primary prevention: 2 trials - AFCAPS/TexCAPS - ACAPS

lovastatin vs placebo

Coronary event by 24% (fully demonstrated)

suggested Coronary death and non fatal MI by 24% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	0.62 [0.34 1.13]	p=1.00	0	7524	2	AFCAPS/TexCAPS,ACAPS,
stroke (fatal and non fatal)	0.73 [0.36 1.45]	p=1.00	0	7524	2	AFCAPS/TexCAPS,ACAPS,
Coronary event	0.76 [0.61 0.93]	p=0.04	0	6605	1	AFCAPS/TexCAPS,
Coronary death and non fatal MI	0.76 [0.61 0.93]	p=0.04	0	6605	1	AFCAPS/TexCAPS,
Coronary death	0.65 [0.30 1.37]	p=1.00	0	7524	2	AFCAPS/TexCAPS,ACAPS,
cardiac death	0.11 [0.01 2.07]	p=1.00	0	919	1	ACAPS,
MACE	no data
Non fatal MI	1.00 [0.29 3.47]	p=1.00	0	919	1	ACAPS,
All cause death	0.99 [0.72 1.35]	p=1.00	0	7524	2	AFCAPS/TexCAPS,ACAPS,
non cardiovascular death	1.19 [0.82 1.71]	p=1.00	0	7524	2	AFCAPS/TexCAPS,ACAPS,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	0.98 [0.70 1.38]	p=1.00	0	6211	1	AFCAPS/TexCAPS,
Death from cancer	no data
Rhabdomyolysis	0.60 [0.08 4.68]	p=1.00	0	7524	2	AFCAPS/TexCAPS,ACAPS,
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Secondary prevention: 7 trials - CCAIT - MARS - AFCAPS/TexCAPS - Weintraub - ACAPS - Sahni - CLAPT

lovastatin vs placebo

Coronary event by 24% (fully demonstrated)

suggested Coronary death and non fatal MI by 24% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	0.62 [0.34 1.13]	p=1.00	0	7524	2	AFCAPS/TexCAPS,ACAPS,
stroke (fatal and non fatal)	0.73 [0.36 1.45]	p=1.00	0	7524	2	AFCAPS/TexCAPS,ACAPS,
Coronary event	0.76 [0.61 0.93]	p=0.04	0	6605	1	AFCAPS/TexCAPS,
Coronary death and non fatal MI	0.76 [0.61 0.93]	p=0.04	0	6605	1	AFCAPS/TexCAPS,
Coronary death	0.78 [0.40 1.53]	p=1.00	0	8509	5	CCAIT,MARS,AFCAPS/TexCAPS,Weintraub,ACAPS,
cardiac death	0.11 [0.01 2.07]	p=1.00	0	919	1	ACAPS,
MACE	no data
Non fatal MI	0.91 [0.38 2.17]	p=1.00	0	1250	2	CCAIT,ACAPS,
All cause death	1.02 [0.75 1.38]	p=1.00	0	8506	5	CCAIT,MARS,AFCAPS/TexCAPS,Weintraub,ACAPS,
non cardiovascular death	1.18 [0.82 1.69]	p=1.00	0	8509	5	CCAIT,MARS,AFCAPS/TexCAPS,Weintraub,ACAPS,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	0.98 [0.70 1.38]	p=1.00	0	6211	1	AFCAPS/TexCAPS,
Death from cancer	no data
Rhabdomyolysis	0.60 [0.08 4.68]	p=1.00	0	7524	2	AFCAPS/TexCAPS,ACAPS,
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

lovastatin vs usual care

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	no data
Coronary death and non fatal MI	no data
Coronary death	0.49 [0.09 2.78]	p=1.00	0	157	1	Sahni,
cardiac death	0.20 [0.01 4.29]	p=1.00	0	226	1	CLAPT,
MACE	no data
Non fatal MI	0.20 [0.01 4.29]	p=1.00	0	226	1	CLAPT,
All cause death	0.63 [0.18 2.18]	p=1.00	0	383	2	Sahni,CLAPT,
non cardiovascular death	1.65 [0.21 12.93]	p=1.00	0	383	2	Sahni,CLAPT,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	no data
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Women: 1 trials - AFCAPS (women subgroup)

Lovastatin vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	n	k	trials
cardiovascular events	0.67 [0.33 1.32]	p=1.00	997	1	AFCAPS (women subgroup) ,
Coronary event	0.67 [0.33 1.32]	p=1.00	997	1	AFCAPS (women subgroup) ,
Cancer	1.14 [0.68 1.92]	p=1.00	997	1	AFCAPS (women subgroup) ,
All cause death	1.57 [0.60 4.08]	p=1.00	997	1	AFCAPS (women subgroup) ,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Diabetes type 2

Diabetic patients with or withour hypercholesterolemia: 1 trials - AFCAPS/TexCAPS (diabetic sub group)

lovastatin vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	no data
retinopathy	no data
vision loss	no data
All cause death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

See more clinical conditions

Primary prevention: 1 trials - AFCAPS/TexCAPS (diabetic sub group)

lovastatin vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	no data
retinopathy	no data
vision loss	no data
All cause death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Lovastatin cholesterol lowering intervention

Mevacor - MK803 - MK 803 - MK-803 - 6 Methylcompactin - 6-Methylcompactin - Monacolin K - Mevinolin - Lovastatin

Cardiovascular prevention

Diabetes type 2

Percutaneous coronary intervention

Peripheral vascular diseases